Resistance emerges to second-generation antiandrogens in prostate cancer

Research output: Contribution to journalArticle

Abstract

The appearance of a mutant androgen receptor, ARF876L, in prostate cancer cells chronically exposed to enzalutamide or ARN-509 promotes a switch from antagonist to agonist receptor function, undermining the potential long-term effectiveness of these second-generation antiandrogen drugs.

Original languageEnglish (US)
Pages (from-to)971-974
Number of pages4
JournalCancer discovery
Volume3
Issue number9
DOIs
StatePublished - Sep 1 2013

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Resistance emerges to second-generation antiandrogens in prostate cancer'. Together they form a unique fingerprint.

  • Cite this